Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | May 23, 2024 | May 24, 2024 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date May 23, 2024 · Filed May 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2034-05-23 | Direct | 67,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 67,000 · Balance 67,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2: The option is fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2: The option is fully vested and exercisable as of the date of the grant.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,600 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 99,600 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
Section 16 reporting ended · disclosed 2018-02-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,393 |
Ending reported balance
After 2018-02-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 221 · Balance 2,936 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 4,846 · Balance 7,782 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Row 3 · 2018-02-21 · Grant · Acquired 1,581 · Balance 9,363 F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 4 · 2018-02-21 · Tax withholding · Disposed 1,647 · Balance 7,716 Row 5 · 2018-02-21 · Gift · Disposed 2,323 · Balance 5,393 F4: Shares gifted to family trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 132,083 |
Reported balance
After 2018-02-21 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-02-21 · Gift · Acquired 2,323 · Balance 132,083 F4: Shares gifted to family trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F4: Shares gifted to family trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2017 Filed Nov 7, 2017 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031522 · form4.xml · nonDerivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 128,433 F3 · shares: Shares gifted to family trust. Read SEC document |
| November 05, 2017 Filed Nov 7, 2017 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031522 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 F3 · shares: Shares gifted to family trust. Read SEC document |
| November 05, 2017 Filed Nov 7, 2017 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,212 | $73.46 | $162,493.52 |
DisclosureSEC source: 0001127602-17-031522 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,003 Read SEC document |
| November 05, 2017 Filed Nov 7, 2017 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031522 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026989 · form4.xml · derivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2017-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,700 | $83.64 | $1,396,774.64 |
DisclosureSEC source: 0001127602-17-026989 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 F3 · price: Sale prices reported for the transactions reported here range from $83.51 to $83.91. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 43,300 | $83.01 | $3,594,514.86 |
DisclosureSEC source: 0001127602-17-026989 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,415 F2 · price: Sale prices reported for the transactions reported here range from $82.50 to $83.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $21.00 | $1,260,000.00 |
DisclosureSEC source: 0001127602-17-026989 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2017 Filed Aug 31, 2017 17:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 115 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026760 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 126,145 F2 · shares: Shares gifted to family trust. Read SEC document |
| August 15, 2017 Filed Aug 31, 2017 17:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 115 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-026760 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 F2 · shares: Shares gifted to family trust. Read SEC document |
| August 15, 2017 Filed Aug 31, 2017 17:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 115 | $59.76 | $6,872.80 |
DisclosureSEC source: 0001127602-17-026760 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,830 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025600 · form4.xml · derivative · entry 5 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,960 Underlying: Common Stock · 820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F1 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 525 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025600 · form4.xml · nonDerivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 126,030 F3 · shares: Shares gifted to family trust. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 525 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025600 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 F3 · shares: Shares gifted to family trust. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 295 | $72.70 | $21,446.50 |
DisclosureSEC source: 0001127602-17-025600 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,240 Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025600 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 4,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007560 · form4.xml · nonDerivative · entry 6 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 125,505 F4 · shares: Shares gifted to family trust. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 4,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007560 · form4.xml · nonDerivative · entry 5 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 F4 · shares: Shares gifted to family trust. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 2,053 | $70.31 | $144,346.43 |
DisclosureSEC source: 0001127602-17-007560 · form4.xml · nonDerivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,069 Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007560 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,122 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2014. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007560 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,100 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2015, and February 1, 2016. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2017 and December 31, 2018, respectively. Read SEC document |
| February 15, 2017 Filed Feb 22, 2017 02:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 213 | $59.33 | $12,637.29 |
DisclosureSEC source: 0001127602-17-007560 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,939 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 42,390 | $0.00 Strike: $72.25 | $0.00 |
DisclosureSEC source: 0001127602-17-004212 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,390 Underlying: Common Stock · 42,390 shares Expires 2027-02-02 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2016 Filed Dec 13, 2016 22:58 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 28,040 | $0.00 Strike: $72.70 | $0.00 |
DisclosureSEC source: 0001127602-16-069950 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,040 Underlying: Common Stock · 28,040 shares Expires 2026-12-10 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · derivative · entry 16 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 9,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested over a five year period with 20% vesting January 18, 2002, the first anniversary of the grant. The options continued to vest in quarterly installments over the next four years, and was fully vested as of January 18, 2006. Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $83.24 | $24,972.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 15 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $83.23 | $16,646.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 14 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,329 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $83.22 | $33,288.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 13 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 800 | $83.21 | $66,568.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 12 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $83.20 | $41,600.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 11 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,729 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 900 | $83.19 | $74,871.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 10 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,172 | $83.18 | $97,486.96 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 9 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,129 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,015 | $83.17 | $167,587.55 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 8 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,301 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,313 | $83.16 | $109,189.08 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 7 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,316 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $83.15 | $16,630.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 6 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,629 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $83.14 | $24,942.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 5 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,829 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $83.13 | $33,252.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 4 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,129 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $83.12 | $16,624.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,529 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $83.09 | $24,927.00 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,729 Read SEC document |
| April 24, 2007 Filed Apr 26, 2007 17:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 9,000 | $7.40 | $66,586.50 |
DisclosureSEC source: 0001179110-07-008457 · edgar.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2007 Filed Mar 2, 2007 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.34 | $0.00 |
DisclosureSEC source: 0001179110-07-005171 · edgar.xml · derivative · entry 5 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,712 Underlying: Common Stock · 3,000 shares Expires 2010-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vested 20% on July 20, 2001, the first anniversary date of the grant. The balance vested 5% quarterly thereafter, and was fully vested as of July 20, 2005. Read SEC document |
| February 28, 2007 Filed Mar 2, 2007 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001179110-07-005171 · edgar.xml · derivative · entry 4 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares vested 20% on January 26, 2001, the first anniversary date of the grant. The balance vested 5% quarterly thereafter, and was fully vested as of January 26, 2005. Read SEC document |
| February 28, 2007 Filed Mar 2, 2007 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,000 | $71.35 | $428,088.00 |
DisclosureSEC source: 0001179110-07-005171 · edgar.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029 Read SEC document |
| February 28, 2007 Filed Mar 2, 2007 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $9.34 | $28,031.40 |
DisclosureSEC source: 0001179110-07-005171 · edgar.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2007 Filed Mar 2, 2007 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $7.08 | $21,234.60 |
DisclosureSEC source: 0001179110-07-005171 · edgar.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2007 Filed Jan 25, 2007 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $65.58 | $0.00 |
DisclosureSEC source: 0001179110-07-001888 · edgar.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2017-01-22 F1 · derivative.exercise_date: Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012. Read SEC document |
| January 22, 2007 Filed Jan 25, 2007 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $65.58 | $0.00 |
DisclosureSEC source: 0001179110-07-001888 · edgar.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · SVP Comm Ops North America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2017-01-22 F1 · derivative.exercise_date: Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.